Design and rationale of a phase 3 study to evaluate the efficacy and safety of nucresiran (ALN-TTRsc04) in patients with transthyretin amyloidosis with cardiomyopathy
17 May 2025 (08:00 - 12:45)
Organised by: 
About the speaker
University College London, London (United Kingdom of Great Britain & Northern Ireland)
6 More presentations in this session
Doctor A. Georgakopoulos (Veria, GR)
Doctor K. Berge (Nordbyhagen, NO)
Doctor N. Khutsishvili (Tbilisi, GE)
Access the full session
The Event
Heart Failure 2025
17 May - 20 May 2025
You may be interested in
Congress Presentation
